The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

Either we get ahead of this crisis or watch a generation of Americans be swept into the devastating grip of disease.

To tackle HIV/AIDS in South Africa, China, through the China Global Development and South-South Cooperation Fund, has announced a two-year funding commitment of 3.49 million U.S. dollars.

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Good morning and welcome, everyone, to today's press briefing from the U.S. Department of State's Africa Media Hub. Today, we are discussing the America First Global Health Strategy and the U.S.

To mark World AIDS Day, the Institute for Contemporary Arts will screen our film tackling the collapse of USAID funding ...

Health Minister Aaron Motsoaledi has welcomed a R65 million injection from China to support South Africa’s HIV prevention ...